Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Vandana Govan
A Novel Vaccine for Cervical Cancer: Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine (Gardasil®)
Therapeutics and Clinical Risk Management
Related publications
Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine
Drugs
Pharmacology
Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males
Drugs in R and D
Pharmacology
Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014
Cancer Epidemiology Biomarkers and Prevention
Medicine
Epidemiology
Oncology
Cervical Cancer and the Human Papillomavirus Vaccine
Journal of Family Planning and Reproductive Health Care
Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women
BMC Infectious Diseases
Infectious Diseases
PCN89 Public Health Impact of Quadrivalent HPV Types 6, 11, 16, 18 Vaccine in Sao Paulo, Brazil Using a Transmission Dynamic Model
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Calibration of a Cost-Effectiveness Model to Evaluate the Incorporation of a Quadrivalent HPV Types 6, 11, 16, 18 Vaccine in Argentina: Disease Burden Component
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Human Medicines European Public Assessment Report (EPAR): Cervarix, Human Papillomavirus Vaccine [Types 16, 18] (Recombinant, Adjuvanted, Adsorbed), Papillomavirus Infections,Uterine Cervical Dysplasia,Immunization, Date of Authorisation: 20/09/2007, Revision: 32, Status: Authorised
Case Medical Research
Estimating the Long-Term Impact of a Prophylactic Human Papillomavirus 16/18 Vaccine on the Burden of Cervical Cancer in the UK
British Journal of Cancer
Cancer Research
Oncology
